ENZC IS ABOUT TO GO GREEN AND THEN THE PANIC BUYS AS PREDICTED...

I gotta get in!!

I don't care that the price is climbing!

YOU GOTTA TO BE IN IT TO WIN IT!!

ENZC ENZC ENZC




ENZC is being FUNDED by WHOM?

Don't KNOW

THAT LAST PR WAS YET ANOTHER INFORMATION RELEASE TO SHAREHOLDERS TO LET THEM KNOW THE STATUSES of ENZC TREMENDOUS ENDEAVORS.

THE FLOAT HAS NOT GROWN SINCE OCTOBER 15, 2020

PLUS, THEY WILL KEEP WORKING UNTIL THERE IS a PARTNERSHIP, BUYOUT or MANY MANY LEASING DEALS.

ANOTHER PR ANOTHER day CLOSER to the BIG BANG!!!!!



AND WITH 24 GREEN FLAGS NOW, IT IS ALL SYSTEMS GO GO GO!!!

WHEN THESE BEAUTY GET 24 GREEN FLAGS, IT MIGHT BE TIME TO TAKE ANOTHER LOOK AT THE STATS...OH YEA

What was the stock 5 months ago?

$0.010

What was the stock 4 months ago?

$0.027

What was the stock 3 months ago?

$0.039

What was the stock 2 months ago?

$0.17

What was the stock 1 month ago?

$0.65


So we are trading at one half of what we were trading at just one month ago.

Why?

The stock ran along with the rest of the OTC and then made a correction and has settle $0.30 cent range while even hitting a TEMPORARY low of $0.22 cents along the way.

ENZC will trade in this RANGE until the stock MOVES UP on its next leg.

WELCOME TO OTC LAND OF THE PUMP AND DUMP SHARE SELLING SCAMS GOING WILD EVERY DAY EXCEPT for ENZC

IF THIS ENZC EVER BREAKS .22, IT WILL BE THE BEGINNING of A MASSIVE and I MEAN MASSIVE REVERSAL.

IT'S NOT TOO LATE TO GET IN ON THIS STATE of the ART ZIP CODE CHANGER .

Rule of thumb when doing DD on DARLING tickers like ENZC is to first check the history of the CEO like CHARLES COTROPIA.

Fantastic Leader

No FRILLS Press Releases

Just the FACTS

HUGE GREEN FLAGS!

ALL SYSTEMS GO GO GO



What was the stock 5 months ago?

$0.010

What was the stock 4 months ago?

$0.027

What was the stock 3 months ago?

$0.039

What was the stock 2 months ago?

$0.17

What was the stock 1 month ago?

$0.65


So we are trading at one half of what we were trading at just one month ago.

Why?

The stock ran along with the rest of the OTC and then made a correction and has settle $0.30 cent range while even hitting a TEMPORARY low of $0.22 cents along the way.

ENZC will trade in this RANGE until the stock MOVES UP on its next leg.

WELL KNOWN FACT THAT BIOTECHNOLOGY COMPANIES like ENZC genarally don't make MONEY for years.

THAT being said ENZC time is coming SOONER than later.

How to Invest in Biotech
Biotech stocks are historically volatile. Often, the value of the stock is all speculative and based on the promise of a new drug or treatment. Until the drug proves viable, receives FDA approval, and hits the market, investing is a big gamble. However, stock prices for these companies are often very low right up until news breaks. If you do your research and get in early, you can make a tremendous amount of money in this sector. Follow these steps to vet any biotech investment you’re considering.

1. Determine the sector
As mentioned, ‘biotech’ can be used as an umbrella term for any pharmaceutical. If you want to invest in a true biotech company, one that works exclusively with biological material, you need to learn about what the company does rather than just looking at its designation.

2. Establish an acceptable risk
Know how much money you’re willing to risk if the stock goes south. Establishing this before you find a company you’re excited about will hopefully help you act judiciously when it’s time to actually pay out for shares rather than acting on impulse and emotion.

3. Know the downsides:
Clinical trial failure: If the drug fails in clinical trials, the company has to essentially start the scientific process over, which can take an enormous amount of time and send its share price spiraling.

Approval delays: Regulatory approval can take a long time. Even if a drug does well in trial, until it comes to market, the stock value might plateau or drop.

Commercialization setbacks: With all approval in place, the company still has to get the drug to market and hope it sells.

4. Assess the company’s history
Learn about the company. See how quickly they’ve gotten other drugs to market and whether or not those drugs have good commercial sales. Biotech companies pop up all the time with no history to review. These investments are particularly risky, but also offer some of the highest potential payouts if they’re successful.

5. Keep your portfolio diversified
Avoid putting too much of your money into the biotech sector. Keep your portfolio diversified in case your investment doesn’t pan out. Greed can lead to devastation.

6. Check-in regularly
Biotech stocks are not investments you can purchase and sit on for years. Keep track of price, volume, and news from the company to see if you should invest in more stock, part with the shares you have before losing money, or sell at a profit.

Tips for Investing in Bio Stocks
Use these 11 tips to help you find great potential investments in the biotech industry and make data-driven, research-based trading decisions.

Know Where the Company is in the Process
It might cost slightly more to get in when a company is out of the clinical trial stage of product development, but it could potentially save you from losing a lot of money if they don’t even make it that far in the process. It’s important to know where the company is in development before buying in.

Consider Risk
Know the risk the company presents. You’ll want to assess history, stage of development, pipeline, partners, cash-on-hand to debt and ‘potential’ cash, and the company’s leadership and reputation. If you feel uneasy about more than two or three of these factors, it might not be the best risk level for you.

Look for Companies With Multiple Plans
It’s tempting to put all your money into a company that’s focused on a single product and putting all its money and resources into it. However, it’s often a safer investing move to find a company that has several ongoing projects in case its front runner fails.

See Who Is Investing
Look and see who’s investing in the company. Often, big-name companies, either in the industry or even some from outside, will put money into the biotech firm’s research and development. You want a solid amount of funding from reputable sources.

Find Companies With Partners
Support, support, support. Any company at risk of going under should their one drug lose viability is not a great investment. Look for companies with partners who can continue project funding should the front-running drug fail at some stage in the development process.

Know the Cash to Biobucks Ratio
The biotech industry uses the term ‘biobucks’ as a synonym for potential payouts should their drug make it to market. Many biotech firms calculate their support using upfront cash and biobucks. If you see an announcement that a biotech firm just got a huge deal, look at the fine print to see how much of that is cash now and how much is conditional.

Look Past the Press Releases
Reading the news about the company and its development progress isn’t enough. You need to dig into its research and see how frequently researchers are performing clinical trials compared to how often you see ‘news’ about the company. You want actual progress, not just the illusion of progress.

Look at the Competition
Multiple companies competing over the same treatment can help boost stock prices, but if you side with the losing company, you could be out a lot of money. Consider investing in companies that don’t have any immediate competition.

Consider the Leadership
Look at the leaders of the company. Learn about their history, management style, risk tolerance, and other characteristics. You want to invest in a company with trustworthy and capable leaders.

Avoid Emotional Investing
If you find yourself getting super excited about a potential investment and itching to hit that buy button without any research, take a minute to calm down. Emotional investing without the facts can lead to disaster in the biotech industry.

We thank everyone for the overwhelming support as we march forward.
#ENZC #HIV #SARS_CoV_2 #NIH #patent #monoclonal #ITV1 #COVID19 #EMA #FDA #ENZCtherapeutics #CDC #EmergingVariants #AI #universal #durable #broadly #neutralizing #mAbs

Who is EVERYONE ENZC is thanking?

CDC on TWITTER makes one go I wonder what that is about.

The market for CORONAVIRUS solutions has been forecasted to reach 75 BILLION DOLLARS by the end of the year.



Will ENZC get a PIECE of that PIE

ENZC currently has a base of around 30 cents and has been there for quite sometime waiting for the NEXT LEG UP.

The company continue to make progress in their BUSINESS activities.

We KNOW what we KNOW.

What we DON"T KNOW:

WHAT is going to HAPPEN?

WHEN is it going to HAPPEN?

The question is:

Will BIG PHARMA jump before the clinical trials are done?

Too MANY POSSIBLITIES for good ole ENZC.

BOOM TIME COMING!!!

The news is just INFORMATION to keep shareholders apprised of the status of ENZC operations.

RESULTS is what we are waiting for and it will be awhile before we see them on the TECHNOLOGY side.

We will see RESULTS on the BUSINESS side when the 2020 ANNUAL Report and the PCAOB AUDIT are RELEASED.

ENZC UNRESTRICTED SHARES KEEP GETTING FLIP TO HIGHER PRICES, HELD BY LONGS, TRADED BY TRADERS HIGHER AND HIGHER OVER AND OVER AGAIN!!!

BOOM TIME COMING!

02/04/2021
$0.3700
$0.5670
$0.3600
$0.4775
122,969,000

12/02/2020
$0.0701
$0.0724
$0.0510
$0.0610
116,770,305

12/01/2020
$0.1176
$0.1176
$0.0600
$0.0750
289,127,906

11/30/2020
$0.0795
$0.1098
$0.0600
$0.1089
180,582,797

11/27/2020
$0.0381
$0.0503
$0.0336
$0.0502
83,732,469

11/25/2020
$0.0420
$0.0430
$0.0275
$0.0330
247,057,906

11/24/2020
$0.0420
$0.0435
$0.0301
$0.0393
187,475,500

11/23/2020
$0.0201
$0.0310
$0.0201
$0.0276
258,472,188

11/20/2020
$0.0135
$0.0200
$0.0131
$0.0194
207,027,203

11/18/2020
$0.0139
$0.0154
$0.0120
$0.0122
145,940,406

10/30/2020
$0.0105
$0.0140
$0.0104
$0.0127
265,230,312

10/16/2020
$0.0123
$0.0123
$0.0099
$0.0108
100,004,000

10/15/2020
$0.0139
$0.0145
$0.0108
$0.0123
113,626,797

10/14/2020
$0.0112
$0.0168
$0.0112
$0.0130
343,720,375

10/13/2020
$0.0130
$0.0130
$0.0094
$0.0107
217,934,594

10/12/2020
$0.0159
$0.0160
$0.0110
$0.0122
206,151,203

10/09/2020
$0.0189
$0.0193
$0.0140
$0.0157
128,021,906

10/08/2020
$0.0142
$0.0190
$0.0138
$0.0171
177,597,906

10/07/2020
$0.0203
$0.0210
$0.0124
$0.0140
218,278,094

10/06/2020
$0.0140
$0.0217
$0.0138
$0.0195
369,954,219

10/05/2020
$0.0067
$0.0146
$0.0067
$0.0140
568,084,500

10/02/2020
$0.0060
$0.0068
$0.0056
$0.0060
108,732,305

10/01/2020
$0.0078
$0.0078
$0.0047
$0.0059
117,175,203

On March 26, 2018, an asset purchase agreement was entered with Immunotech Laboratories, Inc whereby the Exclusive License Agreement for the Patented Immunotherapy Treatment for the care of HIV/Aids and Hepatitis C patients, the Forty Nine Percent ownership in Immunotech Laboratories BG, all equipment and licensing of intellectual property associated with the Patented treatment in exchange for a secured note receivable, common stock of Enzolytics, Inc. issued to Immunotech Laboratories, Inc., and assumption of certain debt from Immunotech by Enzolytics, Inc.

Describe the issuers’ principal products or services, and their markets:

Enzolytics, Inc. is an organization with full indefinite licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. The Company is dedicated to the commercialization of these License rights of the IPF for the treatment of Aids and Hepatitis C as well as potential other treatments for life threatening diseases. IPF is a peptide molecule that has a strong affinity to bind with the HIV virus’ peptide components identified as gp41 and gp120 antigens, rendering them as super antigens, and taking away from them their stealthiness and their capability to destroy the immune system. In addition to this mechanism of action, IPF will also enhance and upgrade the immune system components and criteria, as such resulting in a double impact approach of both behaving as a novel fusion inhibition treatment as well as an immuno-modulator. Enzolytics, Inc., in contrast to other biotech start-ups is based on a proven technological foundation and has scientifically demonstrated that its novel molecule IPF for the treatment of HIV/AIDS is a viable alternative and complimentary treatment product.

ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.

Does ANYONE have any VALID information to the below statement or does anyone know if the below statement have any TRUTH to it?

The EPIC RISE of ENZC has not even begun YET!

Fron trips to the 90s

What wll the next LEG UP deliver?

DOLLARS!!!!

Valued at $23million 4 months ago, now pushing $1billion

Who That?

Enzc
ENzc
ENZc
ENZC

There is no LIMIT for ENZC stock price appreciation!!!

Too much going on with ENZC.

The company could drop press release any time that WILL send the stock past all previous HIGHS!

FACTS we KNOW:

1. AI

2. Monoclonal Antibodies being produced

3. Toxicity study results imminent

4. 19+ Patents

5. 2020 Annual Report imminent

6. PCOAB for 2019 and 2020 expected next month

7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements

8. Charles is in Charge

What we don't know:

1. Relationship to Gileads?

2. Relationship to Eli Lily?

3. Relationship to Immunome?

4. Acquisition?

ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.
ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.


Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.


#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome

The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences These viruses include:

HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens.

We at ENZC follow the SCIENCE and SCIENCE leads to results

FACTS not fiction

1. A PR CAN'T EVEN GET THE PRICE UP. WRONG

Press Releases do not drive up stock prices, RESULTS from the company does.

2. IT'S NOW A SELL THE NEWS DEAL AFTER THAT PR. WRONG

For TRADERS/FLIPPERS only!!! Long term holders will hold their shares for better returns.

3. NO OTHER GREAT NEWS IS COMING ANY TIME SOON. WRONG

Yea right that is a figment of your imagination.

There is no LIMIT for ENZC stock price appreciation!!!

Too much going on with ENZC.

The company could drop press release any time that WILL send the stock past all previous HIGHS!

Many Many things are going on with ENZC.

Many predictions have made and haven't yet come to fruition.

A prediction deferred is not a prediction denied.

Some may expect certain things this week however they may not happen to next week or the week after.

ALL is GOOD!!!!

What we expect that is imminent in the next 15-45 days:

1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. 2020 Annual Report/PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC

BOOM time COMING!!!

PURE wisdom being spouted by the management of this game-changing ENZC!!!

BRAVO I say, BRAVO!

About TRIALS

Company begins process of identifying conserved/immutable target sites on SARS-CoV-2 (the CoronaVirus) and other developments

COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021

In addition, the Company offers this update on its progress toward FDA approval of ENZC's licensed ITV-1 Immunotherapy treatment previously tested in human trials in Bulgaria. On April 29, 2019, Bulgaria, as a member of the European Medicines Agency (EMA), was recognized under the Mutual Recognition Agreement (MRA) between the FDA and European Union for medicinal products for human use subject to limitations. This allows drug inspectors to rely upon information from drug inspections conducted within countries recognized under the Treaty. The limitations stated on the U.S. Food & Drug Administration Website, listed as current as of 5/08/2020, read as follows:

"The capability determinations apply to routine surveillance inspections. In the future the following product and inspection types may be included in the coverage of the agreement, pending further consideration:

Vaccines for human use
Plasma derived pharmaceuticals
Investigational products (clinical trial material)
Veterinary products
Excluded from the MRA scope are: Advanced Therapy Medicinal Products (ATMPs), human blood, human plasma, human tissues and organs and veterinary immunologicals."

To establish the effect of this new directive on the Company, Company representatives visited Sofia, Bulgaria last month and met with the Executive Director of Bulgarian Drug Administration (BDA) to determine how this treaty affects the use of the Company's ITV-1 immunotherapy treatment which was successful in clinical trials completed in 2016. This meeting was followed by a meeting with a Clinical Research Organization, Clinic Design, in Sofia. The Company believes, and is currently reviewing the applicable information, that with the BDA recognition under the MRA and its membership in the European Medicines Agency (EMA), its Immunotherapy treatment should qualify for recognition by the FDA once the Clinical Trial process and Validation order have been completed. The Company has been informed that the inclusion of the BDA in the EMA restricted the permitting of our Treatment by the BDA and the permitting will now be done by the EMA for all the European Union. As a result, some, if not all of the clinical trials may need to be completed under the EMA standards. The company is evaluating the necessary steps and cost for the FDA submission under the Mutual Recognition Agreement between the FDA and EMA.

Based on this information, the Company took the following actions. On January 28th, a notice of default and termination was registered with the courts in Sofia of the Sub License Agreement issued to IMMB BG. The company has entered into negotiations with a supportive group in Bulgaria to form a new entity and enter a funding agreement to cover any new cost of clinical trials under EMA standards and permitting by the EMA. Strategically, the Company believes that the actions will be cost effective resulting in a significant advancement of the Company's therapeutic portfolio.
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html

Enzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting
As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV leading to the planned clinical trials under the European Medicine Agency (the "EMA"). A commitment for funding of the cost of clinical trials under EMA guidelines and cost associated with the issuance of an EMA permit are part of the negotiated agreements. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company's belief is that issuance of the EMA permit for the ITV-1 compound should qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage Clinic Design to begin the clinical trials that is expected to be required under EMA standards. In addition, the Company is negotiating with an International known and respected European Contract Manufacturing organization ("CMO") to manufacture the required quantities of the ITV-1 Treatment to facilitate the clinical trials and permitting process under EMA guidelines.
https://marketwirenews.com/news-releases/enzolytics-finalizes-documentation-with-internationa-8973953024499637.html

CHARLES has EVERYTHING COVERED

The stock price will move according to the the results of the company.

Besides the company unlimited potential, the minor results (getting current, new patent, hired PCAOB auditor, toxicity study etc..) management and board of directors has put ENZC on a trajectory of preeminence.

Will ENZC fill the shoes of such an important distinction?

Time will tell.

The company is just in the development stage with some powerful tools in their closet. The have some processes that the MUST go through to get to the final goals of getting products to the marketplace.

ENZC is very fortunate to be at Texas A&M Institute for Preclinical Studies(TIPS)

TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry, and engineering.

ENZC have shared their plans, goals mission and commitments as well as updates along the way. What they have shared thus far is just a sliver of what is coming down the road.

We are not even 6 months into this journey and the attention the company is getting is unprecedented. They posses some unique technology that may be the answer to help shutting Covid-19 down or at least keeping it in check.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-impo

ENZC treatment is a fraction of the cost for current treatment. We will be able to offer a less expensive product that more people will be able to afford and International aid agencies will purchase it to provide to third world countries.

ENZC has done clinical trials in the past and will be doing clinical trials in the near future in EUROPE.

COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The agreements are with the Company's partners in IMBL formed with a group of successful Bulgarian businessmen.

ENZC already passed Phase III trials. 80% kill rate of HIV:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158404062


As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV leading to the planned clinical trials under the European Medicine Agency (the "EMA"). A commitment for funding of the cost of clinical trials under EMA guidelines and cost associated with the issuance of an EMA permit are part of the negotiated agreements. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company's belief is that issuance of the EMA permit for the ITV-1 compound should qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage Clinic Design to begin the clinical trials that is expected to be required under EMA standards. In addition, the Company is negotiating with an International known and respected European Contract Manufacturing organization ("CMO") to manufacture the required quantities of the ITV-1 Treatment to facilitate the clinical trials and permitting process under EMA guidelines.

For people coming here ASKING for links to CLINICAL trials on ENZC product it is all a farce as information is widely available on the WORLD WIDE WEB!!!

I believe the principals involved in ENZC have a well established, easily researchable track record of HIGH regard to both penny stocks, biotechnology research and making their investors MONEY.

WHY?

This stock was trips last fall and know it is trading around 30 cents and was almost a dollar just weeks ago.


All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.


19+ PATENS

Laboratory at Texas A&M Institute for Preclinical Studies

The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences.

We are good HERE

We are REAL GOOD

Very very HUGE OTC LESSON HERE:


Multiple Millionaires have been made and more WILL BE MADE as ENZC's stock price APPRECIATES!!!


Why?

Activities awaiting updates of what we know about:

1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC

There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be. Anytime


Remember two things.

First and foremost CHARLES is in Charge

Second and very important from the Press Release dated October 19, 2020:

All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.

SPRING is in the Air

BOOM Time COMING

Here is why we are confident in our technology.


It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as “virus escape”. Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.

Mary Pierce

Does a Drug Approval Mean Higher Stock Price?

Answering the question, "Does a Drug Approval Mean a Higher Stock Price?" is fairly straight forward, but there are some caveats that investors need to be aware of. The simple answer is yes, in most cases a new drug approval can lead to a higher share price for the company on the receiving end of that approval. However, each company and approval need to be considered individually so investors can avoid drug approval disappointment.

What Is The Approved Drug?
The word "blockbuster" is often used in association with new drug approvals and history has shown that is exactly what a company needs to have approved to ensure its shares skyrocket post-approval. Examples of potential blockbuster drugs would include, but are not limited to, treatments for cancer, diabetes and sexually transmitted diseases. Another way of looking at this situation is this. A pharmaceutical company has just received approval to sell a new treatment for common allergy symptoms. While that drug may eventually prove to be an important part of the company's revenue stream, it is used to treat a mundane condition and unlikely to really jolt the company's shares.

What Company Is Getting The Approval?
In some cases, the company on the receiving end of a new drug approval is almost as important as what drug is being approved. In this case, before approval, investors should evaluate the potential impact of the new drug on the company's top and bottom lines. For example, there have been examples of small biotechnology companies that, because of funding constraints, only work on one or two major treatments at a given time. Financial markets are aware of this and when those companies land drug approvals, the shares usually surge. On the other hand, an established, large-cap pharmaceuticals company can land a new drug approval, but if that drug is only expected to account for a small percentage of profit and revenue, the approval is unlikely to do much for the share price.

Who Is Doing The Approving?
When it comes to regulatory bodies that affect a drug company's share price, none exceed the importance of the U.S. Food and Drug Administration. Arguably, the only entity that comes remotely close is the European Union's equivalent of the FDA. That is to say a company may get its new blockbuster drug approved in Brazil, but that alone is unlikely to have a significant impact on the shares. The company's investors will want to see the drug approved in the U.S. or Europe, preferably both, for maximum reward on their investment.

Consider Costs
Many new blockbuster drugs, particularly those that treat cancer or genetic diseases, are expensive. Related to the issue of pure cost is whether or not health insurance providers will help their patients make up the difference in purchasing expensive new drugs. Bottom line: If a new drug is ultra-expensive to the point that it cannot be accessed by patients and insurance providers are reluctant to absorb the cost, the manufacturer is not going to sell much of that drug and that is not good for the share price.
https://finance.zacks.com/drug-approval-mean-higher-stock-price-8390.html

Why with so many "other companies" introducing monoclonal antibodies is ENZC needed?

CEOCFO: What are you looking at regarding COVID?


Mr. Cotropia: We have produced an HIV monoclonal antibody that had been successfully tested in five international labs where it neutralized 95% of all strains against which it was tested. There are 6000 different strains of the HIV virus now known. We know that that our antibody is effective and we know the target site on the virus resulting in neutralization of the HIV virus. For an antibody to be effective it has to attack a neutralizable site on the virus that is always there, does not mutate from strain to strain. Knowing the binding site of our HIV monoclonal antibody, and then examining the CoronaVirus amino acid sequence, a correlation in the structures has been identified by our CSO, Dr. Joseph Cotropia, between the CoronaVirus and the HIV virus. With knowledge of these homologous viral structures, monoclonal antibodies will be created that target the corresponding “Achilles Heel” site on the CoronaVirus, an expected conserved immutable and neutralizable site on the virus. Additionally, using artificial intelligence, we will examine the numerous different strains of the virus to identify other conserved sites and produce additional monoclonal antibody targeting them. This is for the purpose of producing a “collection” or “cocktail” of antibodies for therapeutic use. We recognize that there are now known over 16,000 different variations or strains of the CoronaVirus, each slightly different due to mutation. A successful monoclonal antibody “cocktail” therapy must include multiple antibodies that specifically target several immutable sites and which results in neutralization.

For example, we all now know that President Trump received a combination of two Regeneron antibodies. Eli Lilly has also produced an anti-CoronaVirus antibody. However, what we do not know is whether those antibodies will be successful as the virus mutates. As I mentioned, there are now known 16,000 different variants to the CoronaVirus and immutable sites must be the targeted in order to be effective in the long run.

Also, as all experts in the field of monoclonal antibodies agree, including Dr. Anthony Fauci, head of the NIAID/NIH, to have an effective therapy, we must have multiple monoclonal antibodies that target various sites on the virus - and in fact, even President Trump was given a cocktail of two. Therefore, it is imperative to identify conserved neutralizing binding sites on the CoronaVirus, and create multiple monoclonal antibodies that target these critical neutralizable and immutable structures. It is like finding a needle in a haystack and retrieving the needle; you must identify the immutable sites on the virus and then create and characterize fully human monoclonal antibodies that target those sites. The process described here will be our focus and for the reason that success has already been achieved with regard to the production of broadly neutralizing antibodies directed against the HIV virus, we expect success will likewise be achieved in production of broadly neutralizing human monoclonal antibodies directed against the CoronaVirus.

Toxicity and ENZC:

Toxicity or should I say "lack there of" is part of ENZC secret sauce.


The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.

These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
http://enzolytics.com/our-technology/

Inactivated Pepsin Fragment (IPF) Technology

One Company technology, invented by Harry Zhabilov the CSO of the Company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. HIV patients tested in these trials showed the following beneficial outcomes:

Improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8.
Decrease in the viral load.
Demonstrated beneficial effect on opportunistic infections.
Demonstrated very good compatibility with all of the other modern antiretroviral drugs.
Demonstrated very good tolerance in all patients and complete absence of side effects.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage, after which it will be available for patient therapy. ITV-1 also has also demonstrated a positive effect on different kinds of cancer due to its ability to stimulates the immune system.
http://enzolytics.com/our-science/

ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the
first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number
ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into
partnership agreements with newcomers, or with companies in different stages of development in the research pipeline,
combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action.
Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching
over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues,
among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents
impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content

How important is TOXICITY?

What is toxicology?
Toxicology is a field of science that helps us understand the harmful effects that chemicals, substances, or situations, can have on people, animals, and the environment. Some refer to toxicology as the “Science of Safety” because as a field it has evolved from a science focused on studying poisons and adverse effects of chemical exposures, to a science devoted to studying safety.

Toxicology uses the power of science to predict what, and how chemicals may cause harm and then shares that information to protect public health. When talking about toxicology it is important to keep a few things in mind.

Not everyone will respond to substances in exactly the same way. Many factors, including the amount and duration of exposure, an individual’s susceptibility to a substance, and a person’s age, all impact whether a person will develop a disease or not. There are times in a person’s life when he or she may be more susceptible to chemicals. These times may include periods of active cell differentiation and growth in the womb and in early childhood, as well as during adolescence, when the brain is continuing to develop. Just because someone is exposed to a harmful substance, does not always mean they will get sick from it.
The dose of the chemical or substance a person is exposed to is another important factor in toxicology. All substances have the potential to be toxic if given to humans and other living organisms in certain conditions and at certain doses or levels. For example, one or two aspirins may be good for you, but taking a bottle of aspirin may be harmful. The field of toxicology tries to understand and identify at what dose and through what exposure a substance poses a hazard.
Toxicologists also realize that even low-dose exposures that may seem insignificant may have biological meaning or lead to an adverse health effect if the exposure is continuous or happens during a critical window of development.

What is a toxicologist?
A toxicologist is a scientist who has a strong understanding of many scientific disciplines, such as biology and chemistry, and typically works with chemicals and other substances to determine if they are toxic or harmful to humans and other living organisms or the environment.

Just like there are different types of doctors, there are different types of toxicology specialists.

A toxicologist working in the pharmaceutical industry, for example, might work to make sure that potential new drugs are safe for testing in clinical trials for humans.

A toxicologist working at the National Toxicology Program (NTP) might be involved in designing and overseeing studies that create a controlled environment that replicates exposures that humans may encounter. NTP toxicologists work to identify hazards from the chemicals or substances they are studying.
https://www.niehs.nih.gov/health/topics/science/toxicology/index.cfm

How does the science of toxicology improve people’s lives?
Toxicology provides critical information and knowledge that can be used by regulatory agencies, decision makers, and others to put programs and policies in place to limit our exposures to these substances, thereby preventing or reducing the likelihood that a disease or other negative health outcome would occur. For example, the state of California used NTP findings to establish the first in the nation drinking water standard for Hexavalent Chromium. This standard will help reduce people’s exposure to this metallic element. Other benefits of toxicology include:

Government agencies have a sound scientific basis for establishing regulations and policies aimed at protecting and preserving human health and the environment.
Companies, such as pharmaceutical and chemical, are able to develop safer products, drugs, and workplaces.
Consumers have access to information that helps them make decisions about their own health and prevent diseases.

Where is ENZC Laboratory?

Texas A&M University

BIOSCIENCE BUSINESS ACCELERATOR

If you represent an emerging life science technology company, this is your opportunity to collaborate with a top-tier research university and establish your presence on campus, in our dedicated Business Accelerator space.

Speed Up the Commercialization Process

By leasing space in the Texas A&M Bioscience Business Accelerator, located in the Texas A&M Institute for Preclinical Studies (TIPS) facility, you will maximize your access to comprehensive research services and product development support—from inception through clinical trials.

Standard Lease Terms

Standard leasing terms are available for one year of occupancy, with the possibility of annual renewal for two additional years at modest rate increases. Annual renewal consideration is subject to tenants achieving mutually-agreeable technical and business development milestones during their previous lease term.

Business and technology services are designed to allow tenants to graduate from the accelerator within three years. Graduates are encouraged to expand operations into available space in the adjacent Texas A&M University Research Park.

Rental rates are variable based on the growth stage of the applicant and level of engagement between the applicant and the A&M System. Preference will be given to new business ventures and to those companies actively engaging the Texas A&M research community.

Included with Lease

• Office furnishings
• Use of conference rooms and auditorium
• Utilities (excluding any special utility needs)
• Secure key access
• Shared reception services
• Janitorial services
• Use of kitchen and dining area
• Mailbox with dedicated street address

Evaluation Criteria

Tenants are selected based on anticipated growth and potential to provide economic benefits to Texas and the Research Valley, as well as create opportunities for members of the A&M System; Texas A&M faculty, researchers, and students; and local businesses.

Applications are evaluated on the following criteria:

• Legal status
• Biotechnology-based product or service
• Growth potential/economic benefits
• Business plan
• Physical requirements
• Financial capacity

https://vpr.tamu.edu/a-m-research/factsheets/pdfs/bioscience-business-accelerator

ENZ ics not BROKE

In addition to these successes, we have been very successful in raising necessary funding to execute our plans. Our initial $500,000 raise is being followed with $1 million being funded in the next 30 days, and additional investment is being made into the Company by officers of the Company, bringing the total raised since the signing of the non-binding letter of intent to $1.7 million.

ENZC Historical Prices

Date Close Change Change (%) Open High Low Volume
Mar 18 2021 0.3003 -0.0297 -9.0% 0.3231 0.3374 0.2801 17,667,356
Mar 17 2021 0.33 0.00 +0.00% 0.2799 0.3411 0.2509 0
Mar 17 2021 0.33 0.0401 13.83% 0.2799 0.3411 0.2509 33,328,167
Mar 16 2021 0.2899 0.00 +0.00% 0.32 0.328 0.275 0
Mar 16 2021 0.2899 -0.04 -12.12% 0.32 0.328 0.275 39,414,824
Mar 15 2021 0.3299 -0.0298 -8.28% 0.37 0.378 0.32 24,896,764
Mar 12 2021 0.3597 0.0087 2.48% 0.35 0.378 0.345 12,814,866
Mar 11 2021 0.351 0.006 1.74% 0.3448 0.385 0.312 24,275,476
Mar 10 2021 0.345 -0.0399 -10.37% 0.37 0.389 0.33 21,888,042
Mar 09 2021 0.3849 0.00 +0.00% 0.44 0.456 0.36 0
Mar 09 2021 0.3849 -0.0401 -9.44% 0.44 0.456 0.36 36,565,086
Mar 08 2021 0.425 0.037 9.54% 0.41 0.492 0.403 46,999,052
Mar 05 2021 0.388 0.00 +0.00% 0.2499 0.388 0.2204 0
Mar 05 2021 0.388 0.12395 46.94% 0.2499 0.388 0.2204 92,257,923
Mar 04 2021 0.26405 0.00 +0.00% 0.3799 0.386 0.223 0
Mar 04 2021 0.26405 -0.12895 -32.81% 0.3799 0.386 0.223 108,269,174
Mar 03 2021 0.393 -0.085 -17.78% 0.4899 0.4899 0.351 74,644,673
Mar 02 2021 0.478 -0.07 -12.77% 0.54 0.55 0.47 25,158,102
Mar 01 2021 0.548 0.00 +0.00% 0.6599 0.6599 0.54 0
Mar 01 2021 0.548 -0.052 -8.67% 0.6599 0.6599 0.54 17,765,766
Feb 26 2021 0.60 0.00 +0.00% 0.6001 0.6215 0.5285 0
Feb 26 2021 0.60 0.004 0.67% 0.6001 0.6215 0.5285 20,456,533
Feb 25 2021 0.596 -0.054 -8.31% 0.69 0.715 0.59 25,158,550
Feb 24 2021 0.65 0.00 +0.00% 0.6889 0.742 0.627 0
Feb 24 2021 0.65 0.039 6.38% 0.6889 0.742 0.627 48,050,666
Feb 23 2021 0.611 0.00 +0.00% 0.665 0.69 0.47 0
Feb 23 2021 0.611 -0.044 -6.72% 0.665 0.69 0.47 34,926,926
Feb 22 2021 0.655 0.1811 38.21% 0.5499 0.691 0.51 48,952,251
Feb 19 2021 0.4739 0.0928 24.35% 0.42 0.477 0.401 34,624,250
Feb 18 2021 0.3811 0.00 +0.00% 0.499 0.50 0.3688 0
Feb 18 2021 0.3811 -0.1846 -32.63% 0.499 0.50 0.3688 64,273,330
Feb 17 2021 0.5657 -0.0703 -11.05% 0.68 0.69 0.51 24,228,890
Feb 16 2021 0.636 0.00 +0.00% 0.58 0.7152 0.549 0
Feb 16 2021 0.636 0.0869 15.83% 0.58 0.7152 0.549 32,533,151
Feb 15 2021 0.5491 0.00 +0.00% 0.655 0.665 0.471 0
Feb 12 2021 0.5491 -0.11 -16.69% 0.655 0.665 0.471 73,860,125
Feb 11 2021 0.6591 0.00 +0.00% 0.75 0.77 0.60 0
Feb 11 2021 0.6591 -0.0583 -8.13% 0.75 0.77 0.60 38,755,419
Feb 10 2021 0.7174 -0.1116 -13.46% 0.90 0.92 0.55 81,248,598
Feb 09 2021 0.829 0.00 +0.00% 0.811 0.958 0.7472 0
Feb 09 2021 0.829 0.09005 12.19% 0.811 0.958 0.7472 62,155,509
Feb 08 2021 0.73895 0.00 +0.00% 0.5801 0.74 0.579 0
Feb 08 2021 0.73895 0.21495 41.02% 0.5801 0.74 0.579 64,850,555
Feb 05 2021 0.524 0.0465 9.74% 0.537 0.561 0.50 69,397,498
Feb 04 2021 0.4775 0.1345 39.21% 0.37 0.567 0.36 122,968,998
Feb 03 2021 0.343 0.058 20.35% 0.292 0.363 0.2854 84,232,468
Feb 02 2021 0.285 0.00 +0.00% 0.261 0.2929 0.2125 0
Feb 02 2021 0.285 0.0621 27.86% 0.261 0.2929 0.2125 65,928,880
Feb 01 2021 0.2229 0.00 +0.00% 0.1992 0.245 0.19 0
Feb 01 2021 0.2229 0.05 28.92% 0.1992 0.245 0.19 41,865,413
Jan 29 2021 0.1729 -0.0101 -5.52% 0.18 0.19 0.156 31,225,534
Jan 28 2021 0.183 0.00 +0.00% 0.2101 0.215 0.163 0
Jan 28 2021 0.183 -0.029 -13.68% 0.2101 0.215 0.163 32,109,569
Jan 27 2021 0.212 -0.03975 -15.79% 0.265 0.265 0.13 47,653,239
Jan 26 2021 0.25175 0.0538 27.18% 0.214 0.252 0.19895 38,660,307
Jan 25 2021 0.19795 0.02495 14.42% 0.181 0.204 0.174 29,474,663
Jan 22 2021 0.173 0.00 +0.00% 0.168 0.1809 0.165 0
Jan 22 2021 0.173 -0.005 -2.81% 0.168 0.1809 0.165 23,055,231
Jan 21 2021 0.178 0.00 +0.00% 0.187 0.187 0.1575 0
Jan 21 2021 0.178 0.038 27.14% 0.187 0.187 0.1575 42,136,536
Jan 20 2021 0.14 0.0215 18.14% 0.1238 0.19 0.1145 33,079,691
Jan 19 2021 0.1185 -0.0015 -1.25% 0.124 0.125 0.1101 31,549,261
Jan 18 2021 0.12 0.00 +0.00% 0.1321 0.14355 0.1101 0
Jan 15 2021 0.12 0.00 +0.00% 0.1321 0.14355 0.1101 0
Jan 15 2021 0.12 -0.013 -9.77% 0.1321 0.14355 0.1101 28,792,735
Jan 14 2021 0.133 -0.014 -9.52% 0.155 0.155 0.12 40,421,172
Jan 13 2021 0.147 0.03085 26.56% 0.125 0.15 0.121 57,858,990
Jan 12 2021 0.11615 0.02025 21.12% 0.106 0.1162 0.0965 43,999,100
Jan 11 2021 0.0959 0.0164 20.63% 0.0837 0.10 0.0748 46,618,121
Jan 08 2021 0.0795 0.0055 7.43% 0.084 0.0896 0.076 27,471,009
Jan 07 2021 0.074 0.00 +0.00% 0.072 0.074 0.0648 0
Jan 07 2021 0.074 0.007 10.45% 0.072 0.074 0.0648 20,687,387
Jan 06 2021 0.067 0.001 1.52% 0.0699 0.0699 0.0602 20,899,933
Jan 05 2021 0.066 -0.004 -5.71% 0.07 0.0705 0.0501 30,144,396
Jan 04 2021 0.07 -0.0085 -10.83% 0.08 0.081 0.07 24,242,541
Jan 01 2021 0.0785 0.00 +0.00% 0.0799 0.08 0.0655 0
Dec 31 2020 0.0785 0.00165 2.15% 0.0799 0.08 0.0655 21,461,970
Dec 30 2020 0.07685 0.00765 11.05% 0.073 0.085 0.063 50,378,044
Dec 29 2020 0.0692 -0.0007 -1.0% 0.075 0.075 0.065 20,044,658
Dec 28 2020 0.0699 0.00 +0.00% 0.0789 0.08 0.0604 0
Dec 28 2020 0.0699 -0.0036 -4.9% 0.0789 0.08 0.0604 39,142,935
Dec 25 2020 0.0735 0.00 +0.00% 0.0581 0.081 0.0581 0
Dec 24 2020 0.0735 0.00 +0.00% 0.0581 0.081 0.0581 0
Dec 24 2020 0.0735 0.0135 22.5% 0.0581 0.081 0.0581 43,923,355
Dec 23 2020 0.06 0.02041 51.55% 0.044 0.068 0.041 76,007,775
Dec 22 2020 0.03959 -0.01231 -23.72% 0.041 0.05 0.0375 67,370,557
Dec 21 2020 0.0519 -0.0119 -18.65% 0.06 0.06465 0.0395 114,233,315

DILUTION NOT HERE

Stock dilution can also occur when holders of stock options, such as company employees, or holders of other optionable securities exercise their options. When the number of shares outstanding increases, each existing stockholder owns a smaller, or diluted, percentage of the company, making each share less valuable.

Is ENZC being diluted where shares are lees valuble?

NO

The stock has had its up and downs and trading sideways.

It made a move from trips to almost a dollar and has been around 30 cents for quite somtime waitng for the next leg up.

If it was being diluted the stock price would be heading down.

No you are giving the true picture while others are posting false information.

Thanks for keeping it REAL!

HEY DARRON

WHO IS THE OWNER YOU ARE TALKING ABOUT BELOW?

The OWNER himself stated that same person ran a dilution scam on THIS TICKER , the company he owns..

THE OWNER states that people were providing false information about a laboratory that was supposed to be some how linked to this ticker and doing research that is NOT and never has been which was all likely a part of the dilution scam which was ran by the major partner in this thing according to the company OWNER..

Those 3 things together would make a logical person understand that this thing is VERY RISKY at this point..

Why would a stock rise from trips to almost 1$ (one dollar) and settle around 30 cents waiting for the next leg up and has the potential to change the pharmacuetical market in a way never seen before attract so much attention.

As the saying goes:

Where there is smoke there is fire.

ENZC is about the smoke on the next leg up before catching fire.

WATCH OUT!

BOOM TIME COMING!!!

You said:

The fact is, one of the major players in this thing ran an almost identical selling people not many years ago on another ticker making the same type of miraculous claims

The OWNER himself stated that same person ran a dilution scam on THIS TICKER , the company he owns..

THE OWNER states that people were providing false information about a laboratory that was supposed to be some how linked to this ticker and doing research that is NOT and never has been which was all likely a part of the dilution scam which was ran by the major partner in this thing according to the company OWNER..

Those 3 things together would make a logical person understand that this thing is VERY RISKY at this point..


FIRST OFF nobody believes you.

SECOND we don't have no major players.

THIRD who is this GHOST of an OWNER you are TALKING about.

NAME PLEASE

We have the best peer acceptance in the world.

Dr. Anthony Fauci.

He went to court to get our technology.

Will ENZC have a partnership/licensing or be bought out?

Don't know.

If they go the partnership/licensing route, we shareholders can grow with the company.

If they are bought out then at what price?

How many BILLIONS?

A cash buy out would be very expensive and highly unlikely if more than 10 dollars a share. I would expect some type of stock swap and a cash deal.

Rounding up to 2.8 Billion shares the different price valuations are:

2.8 Billion shares at $5 would be 14 Billion Dollars

2.8 Billion shares at $10 would be 28 Billion Dollars

2.8 Billion shares at $20 would be 56 Billion Dollars

2.8 Billion shares at $30 would be 84 Billion Dollars

2.8 Billion shares at $40 would be 112 Billion Dollars

2.8 Billion shares at $50 would be 140 Billion Dollars

2.8 Billion shares at $60 would be 168 Billion Dollars

2.8 Billion shares at $70 would be 196 Billion Dollars

2.8 Billion shares at $80 would be 224 Billion Dollars

2.8 Billion shares at $90 would be 252 Billion Dollars

2.8 Billion shares at $100 would be 280 Billion Dollars

Here is a mega deal from 2019:
Bristol-Myers Squibb (BMY) is angling to become a top-six biopharma after putting up a $74 billion bid to acquire biotech giant Celgene (CELG) early Thursday.
The cash-and-stock deal initially valued Celgene shares at $102.43. The deal offered a 51% premium to the 30-day weighted average closing stock price of Celgene. It was also a 54% premium to the closing price of Celgene stock on Wednesday, Bristol said in a news release.

But the actual value of the deal will be contingent on Bristol stock. Celgene shareholders will receive one Bristol share and $50 cash for each share of Celgene. So the Bristol stock plunge will reduce the effective deal value.

How does one value ENZC?

The company itself suggests markets worth BILLIONS of dollars however what is another company willing to pay for ENZC at this stage?

ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the
first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.

Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents
impacting the human organs, cost, and eventual viral resistance.

In summation our product’s differentiation is based on:

1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation

How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html

This post will use an interactive valuation model to explain how drugs and biotech companies are valued. I'll describe key concepts related to risk and value in biotech, provide some examples of how risk and valuation drive company strategy, and examine whether current biotech valuations are in-line with fundamentals.

The post is accompanied by two tools that can help you apply this knowledge: an interactive drug valuation calculator and an excel spreadsheet with an example of how a drug company might be valued.

Value at start of program
$0M
Probability of FDA approval: 4%

Investment required for approval: $559M

Value at start of Phase 1
$88M
Probability of FDA approval: 12%

Investment required for approval: $520M

Value at start of Phase 2
$248M
Probability of FDA approval: 20%

Investment required for approval: $486M

Value at start of Phase 3
$1,119M
Probability of FDA approval: 56%

Investment required for approval: $405M


Risk and value in biotech

Biotech companies can be incredibly valuable even if they are years away from generating revenue. We can't use typical valuation metrics to value pre-revenue biotech companies, but biotech has its own valuation principles. A few of note:

Value is closely tied to risk: In other industries, growth, either of profits, revenues, or users, drives value creation. In drug development, derisking drives value creation. Companies "derisk" their science by conducting scientific experiments or clinical studies. The more rigorous the experiment, the more value is created if the experiment is successful.

Risk is often binary: Because value creation is tied to risk reduction, and because risk is reduced through experiments and studies, a company's value often changes dramatically when new data from studies is released. Because studies are generally blinded to prevent bias, the data from a study is usually revealed all at once at the end of a study. So big swings in value can happen literally overnight. Positive binary events often catalyze a fundraise.

Drugs become exponentially more valuable over time: Drugs aren't really that valuable until around Phase 2. This is why most venture capitalists prefer to fund companies that develop their own drugs rather than just discover new targets or hits and then try to sell them to pharma. In our model, each hit is worth $2.7M and it costs $2.1M to get each hit. A Phase 2 molecule is worth $249M and it costs $74M to get to Phase 2. A Phase 3 molecule is worth $1.1B and it costs $154M to get to that point. Unless you can generate high-quality hits or leads very quickly and cheaply, you're better off taking drugs to the clinic yourselves rather than partnering too early.

Valuations are highly sensitive to discount rate: It takes a long time to develop drugs, and most of the value is created after many years, so a drug's value is highly sensitive to the discount rate. Developing drugs requires lots of capital, and because drug development is risky, capital can be expensive. So cost of capital can be one of the biggest components of the cost of drug development. Try changing the discount rate in the model below to 2% (roughly the rate of inflation). Drugs become much more valuable. As a corollary, lower discount rates can allow companies to drastically reduce drug prices. Check out this drug pricing calculator to see how discount rate affects price.

TWEETS discovered TWEETS uncovered

ENZC mentioned using AI to help identify conserved , immutable targets against HIV virus and the SARs-Cov-2 virus in their 2020 year end update. In just about a month later on February 1, 2021 ENZC announces in a press release it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. In the same release they and I quote:

Quote:
Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced.


Then comes the TWEETS:

So we have a tweet from February 18, 2021 mentioning going one step beyond, AI, abrogate the harmful effects of the variations of mutations and COVID-19.

Then on February 21, 2021 we have a tweet mentioning emergence of variants of concern, concerns with Vaccine effectiveness in the face of viral mutations, groundbreaking solution, big news coming up next week, mutations, AI, patents, innovation and monoclonal antibody.

Then on March 8, 2021 yet another TWEET:

Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.


#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome

Then on March 16, 2021 yet another TWEET:

Enzolytics takes rapid strides in achieving one of the many milestones.

$ENZC #HIV #ENZC #OTCQB #COVID19 #EMA #FDA #patents ITV-1.

So the tweets make sense because in the February 1, 2021 PR ENZC said and I quote:

Supporting DATA:

Our new lab is being opened on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Here we will expand our development capabilities for the production of additional monoclonal antibodies targeting immutable sites on the HIV and SARS-CoV-2 viruses. In addition to those primary targets on these viruses already known to us, we have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.
The significance of this step is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective, initially developed therapeutics. We have all now heard of the new variants of the CoronaVirus that have just surfaced this week in the United Kingdom and South Africa. Such variants have been found to now exist in the U.S. Due to mutation, these variants have slightly different structures from the virus as initially introduced into the U.S. and will require different therapeutics to address them. The necessary response to such mutations is to identify sites on the virus that do not mutate - that are immutable - and to produce monoclonal antibodies targeting these immutable sites. Using artificial intelligence, we expect to be able to identify these sites such that antibodies may be produced targeting them. This is one of our focuses.
https://marketwirenews.com/news-releases/enzolytics-inc-2020-year-end-update-6713954951124293.html

COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies.
The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.


Additionally, the Company's Genetics and Molecular Biology data science team is now screening (using Computer analysis/Artificial Intelligence [AI]) more than 275,000 CoronaVirus isolates now known, to also identify conserved sites which expectedly are immutable. From this information, anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies will be produced.

The significance of producing monoclonal antibodies against conserved target sites on targeted viruses is made evident by the mutant strains of the CoronaVirus currently surfacing in the U.S, South Africa, Brazil, United Kingdom and around the world. The same virus mutation exists with HIV, as well as other well-known viruses. As a virus mutates, a therapeutic becomes ineffective when it neutralizes by attacking a site that changes. By targeting an immutable site, a therapeutic is not affected by the mutation. This is well understood by the necessity to produce a new flu vaccine with each flu season, namely because the flu virus mutates. Producing therapeutics that target a conserved site on viruses makes possible the production of a therapeutic that is not rendered ineffective by virus mutation, and therefore can be applied successfully both universally around the world and durably over time.
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html


At Enzolytics, we go one step beyond by applying Artificial Intelligence to abrogate the harmful effects of the variations that might be more transmissible; more lethal than merely just "monitoring" and "identifying" the virus mutations.#ENZC#COVID-19
1:28 PM · Feb 18, 2021·Twitter Web App

With the emergence of variants of concern and concerns with Vaccine effectiveness in the face of viral mutations, Enzolytics comes up with a groundbreaking solution. Big news coming up next week. #SARS-CoV2 #mutations #AI #patents #innovation #monoclonalantibody #enzc
3:03 PM · Feb 21, 2021·Twitter Web App

ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.

ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.

Toxicity and ENZC:

Toxicity or should I say "lack there of" is part of ENZC secret sauce.


The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.

These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
http://enzolytics.com/our-technology/

Inactivated Pepsin Fragment (IPF) Technology

One Company technology, invented by Harry Zhabilov the CSO of the Company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. HIV patients tested in these trials showed the following beneficial outcomes:

Improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8.
Decrease in the viral load.
Demonstrated beneficial effect on opportunistic infections.
Demonstrated very good compatibility with all of the other modern antiretroviral drugs.
Demonstrated very good tolerance in all patients and complete absence of side effects.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage, after which it will be available for patient therapy. ITV-1 also has also demonstrated a positive effect on different kinds of cancer due to its ability to stimulates the immune system.
http://enzolytics.com/our-science/

ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the
first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number
ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into
partnership agreements with newcomers, or with companies in different stages of development in the research pipeline,
combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action.
Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching
over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues,
among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents
impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content

How important is TOXICITY?

What is toxicology?
Toxicology is a field of science that helps us understand the harmful effects that chemicals, substances, or situations, can have on people, animals, and the environment. Some refer to toxicology as the “Science of Safety” because as a field it has evolved from a science focused on studying poisons and adverse effects of chemical exposures, to a science devoted to studying safety.

Toxicology uses the power of science to predict what, and how chemicals may cause harm and then shares that information to protect public health. When talking about toxicology it is important to keep a few things in mind.

Not everyone will respond to substances in exactly the same way. Many factors, including the amount and duration of exposure, an individual’s susceptibility to a substance, and a person’s age, all impact whether a person will develop a disease or not. There are times in a person’s life when he or she may be more susceptible to chemicals. These times may include periods of active cell differentiation and growth in the womb and in early childhood, as well as during adolescence, when the brain is continuing to develop. Just because someone is exposed to a harmful substance, does not always mean they will get sick from it.
The dose of the chemical or substance a person is exposed to is another important factor in toxicology. All substances have the potential to be toxic if given to humans and other living organisms in certain conditions and at certain doses or levels. For example, one or two aspirins may be good for you, but taking a bottle of aspirin may be harmful. The field of toxicology tries to understand and identify at what dose and through what exposure a substance poses a hazard.
Toxicologists also realize that even low-dose exposures that may seem insignificant may have biological meaning or lead to an adverse health effect if the exposure is continuous or happens during a critical window of development.

What is a toxicologist?
A toxicologist is a scientist who has a strong understanding of many scientific disciplines, such as biology and chemistry, and typically works with chemicals and other substances to determine if they are toxic or harmful to humans and other living organisms or the environment.

Just like there are different types of doctors, there are different types of toxicology specialists.

A toxicologist working in the pharmaceutical industry, for example, might work to make sure that potential new drugs are safe for testing in clinical trials for humans.

A toxicologist working at the National Toxicology Program (NTP) might be involved in designing and overseeing studies that create a controlled environment that replicates exposures that humans may encounter. NTP toxicologists work to identify hazards from the chemicals or substances they are studying.
https://www.niehs.nih.gov/health/topics/science/toxicology/index.cfm

How does the science of toxicology improve people’s lives?
Toxicology provides critical information and knowledge that can be used by regulatory agencies, decision makers, and others to put programs and policies in place to limit our exposures to these substances, thereby preventing or reducing the likelihood that a disease or other negative health outcome would occur. For example, the state of California used NTP findings to establish the first in the nation drinking water standard for Hexavalent Chromium. This standard will help reduce people’s exposure to this metallic element. Other benefits of toxicology include:

Government agencies have a sound scientific basis for establishing regulations and policies aimed at protecting and preserving human health and the environment.
Companies, such as pharmaceutical and chemical, are able to develop safer products, drugs, and workplaces.
Consumers have access to information that helps them make decisions about their own health and prevent diseases.

Where is ENZC Laboratory?

Texas A&M University

BIOSCIENCE BUSINESS ACCELERATOR

If you represent an emerging life science technology company, this is your opportunity to collaborate with a top-tier research university and establish your presence on campus, in our dedicated Business Accelerator space.

Speed Up the Commercialization Process

By leasing space in the Texas A&M Bioscience Business Accelerator, located in the Texas A&M Institute for Preclinical Studies (TIPS) facility, you will maximize your access to comprehensive research services and product development support—from inception through clinical trials.

Standard Lease Terms

Standard leasing terms are available for one year of occupancy, with the possibility of annual renewal for two additional years at modest rate increases. Annual renewal consideration is subject to tenants achieving mutually-agreeable technical and business development milestones during their previous lease term.

Business and technology services are designed to allow tenants to graduate from the accelerator within three years. Graduates are encouraged to expand operations into available space in the adjacent Texas A&M University Research Park.

Rental rates are variable based on the growth stage of the applicant and level of engagement between the applicant and the A&M System. Preference will be given to new business ventures and to those companies actively engaging the Texas A&M research community.

Included with Lease

• Office furnishings
• Use of conference rooms and auditorium
• Utilities (excluding any special utility needs)
• Secure key access
• Shared reception services
• Janitorial services
• Use of kitchen and dining area
• Mailbox with dedicated street address

Evaluation Criteria

Tenants are selected based on anticipated growth and potential to provide economic benefits to Texas and the Research Valley, as well as create opportunities for members of the A&M System; Texas A&M faculty, researchers, and students; and local businesses.

Applications are evaluated on the following criteria:

• Legal status
• Biotechnology-based product or service
• Growth potential/economic benefits
• Business plan
• Physical requirements
• Financial capacity

https://vpr.tamu.edu/a-m-research/factsheets/pdfs/bioscience-business-accelerator